HDAC9 and Miyoshi myopathy: HDACi (Panobinostat, Vorinostat) were used as single agents or in combination with other anti-MM agents in several phase II and III clinical trials and showed promising clinical activity, although there was significant toxicity and agents allowing for a more selective targeting of HDAC are required.